HIV drug switch may protect hearts: small study tests doravirine

NCT ID NCT04820933

Completed Disease control Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed early-phase trial tested whether switching HIV medications to doravirine (with emtricitabine and tenofovir alafenamide) could improve cholesterol and reduce early signs of artery hardening compared to staying on integrase inhibitors. Twenty-six adults with well-controlled HIV and high cholesterol took part. The study measured blood markers linked to heart disease risk, not actual heart events.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Doravirine 100 mg (with emtricitabine and tenofovir alafenamide)
What this could lead to: If successful, this could show that doravirine is a better option for people with HIV to lower their risk of heart disease and improve cholesterol levels.
What could go wrong: This is a very small, early-phase study with only 26 participants, so results may not apply to everyone. It looked at lab markers, not actual heart attacks, so real-world benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR RISK FACTOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder HIV infectious disease inherited lipid metabolism disorder Lipid Metabolism Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR RISK FACTOR HIV I INFECTION LIPID METABOLISM DISORDERS

Contacts and locations

Locations

University of Texas Southwestern

Dallas, Texas, 75219, United States
University of Texas Southwestern Medical Center

Dallas, Texas, 75219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.